CareDx, Inc. regulatory filings document the public-company record for a Nasdaq-listed precision medicine company serving transplant patients and caregivers. The company’s 8-K and proxy materials cover operating and financial results for testing services, patient and digital solutions, laboratory products, and clinical or regulatory disclosures tied to non-invasive molecular testing for organ transplantation.
CareDx filings also address material agreements, capital-structure matters for its common stock, shareholder voting items, board governance, executive compensation, inducement and other equity awards, and officer-role changes. Other-event disclosures include governance and legal-contingency materials, including shareholder derivative litigation settlement documents when filed.
CareDx, Inc. executive Keith Kennedy, the company’s CFO and COO, reported a routine tax-related share withholding. On the vesting of restricted stock units, 11,725 shares of common stock were withheld by the issuer at $17.87 per share to cover tax obligations.
Following this tax-withholding disposition, Kennedy directly holds 197,414 shares of CareDx common stock. The transaction reflects compensation-related share settlement mechanics rather than an open-market purchase or sale.
CareDx, Inc. Chief Commercial Officer Jessica Meng reported a tax-related share disposition tied to vested restricted stock units. On the vesting of these RSUs, 7,386 shares of Common Stock were withheld by CareDx at $17.87 per share to cover tax withholding obligations.
After this non-market, tax-withholding transaction, Meng directly holds 169,392 shares of CareDx common stock. The event reflects routine share withholding for taxes rather than an open-market sale or purchase decision.
CareDx, Inc. reported that Secretary and General Counsel Jeffrey Adam Novack had 3,987 shares of common stock withheld on April 1, 2026 to cover tax obligations tied to the vesting of restricted stock units. These shares were retained by the company rather than sold in the market. After this tax-withholding transaction, he directly holds 121,377 shares of CareDx common stock.
Goldberg Michael reported acquisition or exercise transactions in this Form 4 filing.
CareDx, Inc. director Michael Goldberg received an automatic quarterly grant of 1,981 shares of common stock on 2026-04-02. The shares were granted at no cash cost in lieu of cash non-employee director compensation under the company’s Outside Director Compensation Policy. Following this award, he directly holds 185,942 common shares.
CareDx, Inc. director Michael Goldberg exercised stock options to acquire additional common shares. On March 31, 2026, he exercised options covering 26,500 shares of CareDx common stock at exercise prices of $5.02, $4.95, and $1.22 per share.
Following these option exercises, Goldberg directly owned 183,961 shares of CareDx common stock. The exercised options were originally subject to vesting schedules beginning in 2016 and 2017, with monthly vesting thereafter as described in the filing footnotes. No sales or gifts were reported in this filing.
CareDx Inc Schedules an Amendment No. 9 to a Schedule 13G/A showing 0 shares beneficially owned, representing 0% of Common Stock as of 03/13/2026.
The filing explains an internal realignment at The Vanguard Group on 01/12/2026, after which certain Vanguard subsidiaries report holdings separately in reliance on SEC Release No. 34-39538. The filing is signed by a Vanguard officer on 03/26/2026.
CareDx, Inc. reported solid growth for the fourth quarter and full year 2025 and outlined its 2026 outlook, while also announcing a Chief Financial Officer transition. Full‑year 2025 revenue reached $380 million, up 14% from 2024, with Q4 2025 revenue of $108 million, up 25% year over year. Testing services generated $275 million for 2025, rising 10%, and patient and digital solutions and product revenue grew 31% and 19%, respectively. The company posted a 2025 GAAP net loss of $21 million but achieved non‑GAAP net income of $32 million and adjusted EBITDA of $32 million. CareDx ended December 31, 2025 with about $201 million in cash, cash equivalents, and marketable securities after repurchasing $88 million of stock. For 2026, it expects revenue of $420–$444 million and adjusted EBITDA of $30–$45 million. The board appointed Keith Kennedy as Chief Financial Officer and Chief Operating Officer effective February 26, 2026, while Nathan Smith resigned as CFO effective February 25, 2026 and will receive severance, a $91,643 2025 bonus, COBRA reimbursements, and vesting of 5,840 restricted stock units.
CareDx, Inc. files its annual report describing a focused transplant-diagnostics business built around AlloSure, AlloMap, HeartCare, AlloHeme, AlloCell and AlloSeq product lines, plus digital and pharmacy services for transplant centers.
The company reported a net loss of $21.4 million for the year ended December 31, 2025, compared with net income of $52.5 million in 2024, and an accumulated deficit of $735.4 million. In 2025 it performed about 200,000 commercial tests, with Medicare providing roughly 46% of testing-services revenue.
AlloSure blood-based rejection tests (kidney, heart, lung) are reimbursed by Medicare at $2,753 per test effective January 1, 2026, an $88 reduction for AlloSure Kidney. As of February 19, 2026, 51,216,344 common shares were outstanding, and CareDx employed 765 people, mainly in the United States and Europe.
CareDx reported strong growth for 2025 while reshaping its leadership team. Full-year revenue reached $380 million, up 14% from 2024, with Q4 revenue of $108 million, up 25%. Testing services, patient and digital solutions, and product revenue all grew double‑digits.
The company posted a 2025 GAAP net loss of $21 million, but delivered non‑GAAP net income of $32 million and adjusted EBITDA of $32 million. Cash, cash equivalents and marketable securities were about $201 million as of December 31, 2025 after $88 million of share repurchases. For 2026, CareDx guides revenue to $420–$444 million and adjusted EBITDA of $30–$45 million.
The Board appointed Keith Kennedy as Chief Financial Officer and Chief Operating Officer, effective February 26, 2026, following the resignation of CFO Nathan Smith for personal reasons. Smith will receive severance including nine months’ salary, a $91,643 bonus, COBRA premium reimbursement for nine months, and vesting of 5,840 restricted stock units.
CareDx, Inc. (CDNA) received an updated ownership report on its common stock from investment manager Neil Gagnon and related entities. As of the reported date, Gagnon reports beneficial ownership of 3,054,946 shares of CareDx common stock, representing 5.9% of the class.
Within this total, Gagnon Securities LLC reports beneficial ownership of 2,213,827 shares, or 4.3% of the class, and Gagnon Advisors, LLC reports 532,892 shares, or 1.0%. The filing states the securities are not held for the purpose of changing or influencing control of CareDx.